RemeGen Co (HKSE:09995) Research & Development: HK$628 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09995 RemeGen Co Ltd HKSE:09995
46 GF Score
Price HK$80.40
GF Value HK$209.14
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co Research & Development?

RemeGen Co HKSE:09995 +0.12% 46 Research & Development is HK$628 Mil as of Dec. 2025. GuruFocus rates HKSE:09995 with a GF Score™ of 46/100 and a GF Value™ of HK$209.14 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. RemeGen Co's Research & Development for the three months ended in Dec. 2025 was HK$363 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$628 Mil.

RemeGen Co  (HKSE:09995) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

RemeGen Co Research & Development Related Terms

RemeGen Co Research & Development Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Research & Development Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 870.56 1,096.70 1,428.81 1,643.98 1,346.38

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 412.52 0.00 265.96 362.53 0.00
HKSE:09995
46GF Score
RemeGen Co Ltd HKSE:09995
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$628 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$628 Mil mean?
RemeGen Co (HKSE:09995) has a Research & Development of HK$628 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on RemeGen Co and its competitors.
Is RemeGen Co's Research & Development too high?
RemeGen Co's current Research & Development is HK$628 Mil. Overall, RemeGen Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Research & Development compare to VRTX and REGN?
RemeGen Co's Research & Development of HK$628 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on RemeGen Co and its competitors. RemeGen Co's current Research & Development is HK$628 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (HKSE:09995) is currently considered Possible Value Trap. The stock's GF Value™ is HK$209.14, compared to a current price of HK$80.40 — trading 61.6% below its estimated fair value. The current Research & Development is HK$628 Mil. RemeGen Co's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For RemeGen Co (HKSE:09995), the current Research & Development is HK$628 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (HKSE:09995) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of HK$80.40 is trading 61.6% below its estimated GF Value™ of HK$209.14. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for HKSE:09995:

  • Research & Development: HK$628 Mil
  • GF Value™: HK$209.14 vs. price of HK$80.40 (61.6% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HKSE:09995 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
46GF Score

Get the complete analysis for HKSE:09995

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$80.40
Price
HK$209.14
GF Value